Following Richard Barry’s last SRPT Buy transaction on March 16, 2016, the stock climbed by 109.6%. In addition to Richard Barry, one other SRPT executive reported Buy trades in the last month.
Based on Sarepta Therapeutics’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $94.67 million and GAAP net loss of $276 million. In comparison, last year the company earned revenue of $73.53 million and had a GAAP net loss of $109 million. The company has a one-year high of $165.87 and a one-year low of $95.21. The Company has a Price to Book ratio of 8.5305.
Starting in May 2019, SRPT received 32 Buy ratings in a row. 15 different firms, including Merrill Lynch and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on Sarepta Therapeutics has been neutral according to 31 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.